Progyny, Inc. - Common Stock (PGNY)

Record selling season and raised guidance as new covered lives climb.

Fertility benefits company Progyny (NASDAQ:PGNY) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.9% year on year to $341.3 million. The co...

Progyny (NASDAQ:PGNY) raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season. The fertility and family-building benefits company expects the majority of th

Fertility benefits company Progyny (NASDAQ:PGNY) met Wall Street’s revenue expectations in Q3 2026, with revenue up 8.9% year on year to $341.3 million. The ...

Fertility benefits company Progyny (NASDAQ:PGNY) will be reporting results this Wednesday after the bell. Here’s what to expect. Progyny beat analysts’ reven...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

What a fantastic six months it’s been for Progyny. Shares of the company have skyrocketed 51.1%, hitting $27.77. This performance may have investors wonderin...

What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 6% in the afternoon session after the company announced that its annual sell...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Let’s dig into the relative performance of Progyny (NASDAQ:PGNY) and its peers as we unravel the now-completed Q2 health insurance providers earnings season....

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Progyny (NASDAQ:PGNY) CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year. Spea

Record revenue and gross profit as client count climbs to 604 and member base expands.

Progyny’s second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expec...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 4.5% in the afternoon session after the company issued a weak forecast, oversh...